Table 2 Adverse events according to MedDRA SOC by study group
CQ (N = 45) | CQ-MB (N = 181) | |
|---|---|---|
Gastrointestinal disorders | 23 (38.3%) | 93 (41.5%) |
Respiratory disorders | 16 (26.7%) | 78 (34.8%) |
Infections and infestations | 10 (16.7%) | 38 (17.0%) |
Skin and subcutaneous tissue disorders | 8 (13.3%) a | 9 (4.0%) a |
Others | 3 (5.1%) | 6 (2.7%) |